Gem 3 new shares issued below purchase less than 980,000 yuan

After every reporter Chenghongyong after the big stock Everbright Bank (601818) yesterday issued, today's a-share market ushered in Ssangyong Shares (300108), new Open Source (300109), Huaren Pharmaceutical (300110) and other 3 gem stock online distribution. Interestingly, due to the circulation of only 9 million shares, the new open source has become a share market IPO shares of the least number of stocks, while the below purchase 3 stocks also less than 980,000 yuan.　　Integrated company fundamentals and growth, and other factors, analysts believe that investors can focus on Ssangyong shares, Huaren Pharmaceutical industry can be a suboptimal choice. New Open source Create the smallest new open source this IPO circulation only 9 million shares, a a-share IPO circulation minimum record is also refreshed!　　And the previous record-keeping is also from the gem, including the stock (300074, closing price of 66.70 Yuan) and huaxing Venture (300025, closing price of 27.59 yuan) two stocks, two companies IPO circulation is 10 million shares. In addition, according to the listing arrangements, the new open source after the IPO will be only 7.2 million shares of online distribution, which also makes it beyond the Juloka (300099, closing price of 78.00 Yuan), the share market as the smallest share of the stock.　　Juloka on August 6, the current number of circulating capital is 8.34 million shares. Data show that the new open source for 30.00 yuan/share price, corresponding to the issue of 61.22 times times, two cohabitation in the first round of shares, its online circulation of 7.2 million shares, investors can purchase the maximum of 7000 shares.　　New Open source is mainly engaged in the development of PvP products, production and sales, is the largest manufacturer of PvP. In addition, the Huaren pharmaceutical industry in the proposed public offering of not more than 53.6 million shares, is 3 of the largest circulation, of which 42.88 million shares on the Internet, the issue price of 13.99 yuan, the issuance of P/E multiples of 50.38 times times, the purchase limit of 40,000 shares.　　Huaren Pharmaceutical Business for non-PVC soft bag infusion and related products, research and development, production and sales, with the largest non-PVC soft bag large infusion monomer factory. Ssangyong shares a circulation of 1300 shares, the issue price of 20.48 yuan/shares, the issuance of P/E multiples of 53.14 times times, its online circulation of 10.4 million shares, up to the purchase of 10,000 shares.　　Ssangyong shares the main business of high disperse white carbon black products production and sales. Below purchase only need 974,400 yuan and the past more than 1 million yuan, more than millions of yuan, investors today below purchase 3 new shares up to less than 1 million yuan. According to the purchase limit and the issue price calculation, the full purchase Ssangyong shares, new open source and huaren pharmaceutical investors need to use the amount of funds of about 974,400 yuan.　　Among them, the full purchase Ssangyong shares, Huaren pharmaceutical industry is 204,800 yuan, 210,000 yuan respectively. For investors who are not ready for full purchase, Century Securities gem analyst Lu Lihua suggested that investors can choose Ssangyong shares for the first choice, this is mainly based on fundamentals and growth highlights of the consideration, and Huaren pharmaceutical industry can also be a secondary choice. In terms of growth and overall profitability, the three companies in 2009 were higher than the average of 106 gem companies issued. Among them, Ssangyong shares and Huaren pharmaceutical industry's overall profit level is relatively high.　　Data show that Ssangyong shares, Huaren pharmaceutical Industry 2009-year gross profit margin of 54.33%, 57.05%, and new open source is 29.9%. And as a high dispersion of white carbon black market leading and national High-tech Enterprises, Ssangyong is one of the earliest production of white carbon black enterprises, but also the only domestic sentinel production of national defense chemical precipitation method of white carbon black enterprises.　　According to Guotai forecast, Ssangyong shares 2010 ~2012 Annual diluted EPS is 0.6 yuan, 0.88 yuan, 1.15 yuan respectively. For Huaren pharmaceutical industry, Lu Lihua that, as the domestic non-PVC soft pack Infusion leader, the company's products positioning high-end, and benefited from the new health reform and infusion industry upgrade, the market prospects are good. However, Lu Lihua said that the large infusion industry competition is fierce, product replacement speed, which will make the company face greater challenges; and huaren pharmaceutical industry in the comprehensive technical advantages, relative to the rival double Crane Pharmaceutical (600062, closing price 26.73 yuan), the Cologne pharmaceutical industry (002422, closing price 103.80 ) or somewhat weaker. According to its estimate, participates in this round on-line purchase the freezing fund to be about 340 billion yuan, and 3 new stock's average check rate is about 0.51%.